1-isopentyl-4-(isopentylamino)-6-methylpyridin-2(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-isopentyl-4-(isopentylamino)-6-methylpyridin-2(1H)-one
• 英文别名: 6-Methyl-1-(3-methylbutyl)-4-(3-methylbutylamino)pyridin-2-one；6-methyl-1-(3-methylbutyl)-4-(3-methylbutylamino)pyridin-2-one
• 化学式: C₁₆H₂₈N₂O
• 分子量: 264.411
• InChiKey: CRGJBALPHNUUGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-羟基-6-甲基-2-吡喃酮 以 乙二醇二甲醚 、 水 为溶剂， 反应 12.67h， 生成 1-isopentyl-4-(isopentylamino)-6-methylpyridin-2(1H)-one
  参考文献：
  名称：

  A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin

  摘要：

  The clonidine-like central antihypertensive agent rilmenidine, which has high affinity for I-1-type imidazoline receptors (I-1-IR) was recently found to have cytotoxic effects on cultured cancer cell lines. However, due to its pharmacological effects resulting also from alpha(2)-adrenoceptor activation, rilmenidine cannot be considered a suitable anticancer drug candidate. Here, we report the identification of novel rilmenidine- derived compounds with anticancer potential and devoid of alpha(2)-adrenoceptor effects by means of ligand-and structure-based drug design approaches. Starting from a large virtual library, eleven compounds were selected, synthesized and submitted to biological evaluation. The most active compound 5 exhibited a cytotoxic profile similar to that of rilmenidine, but without appreciable affinity to alpha(2)-adrenoceptors. In addition, compound 5 significantly enhanced the apoptotic response to doxorubicin, and may thus represent an important tool for the development of better adjuvant chemotherapeutic strategies for doxorubicin-insensitive cancers. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.043

文献信息

• Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability
  作者：Lisa Giannessi、Maria Giovanna Lupo、Ilaria Rossi、Maria Grazia Martina、Antonietta Vilella、Martina Bodria、Daniela Giuliani、Francesca Zimetti、Ilaria Zanotti、Francesco Potì、Franco Bernini、Nicola Ferri、Marco Radi

  DOI：10.1016/j.ejmech.2023.116063

  日期：2024.2
• A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin
  作者：Jelica Vucicevic、Tatjana Srdic-Rajic、Marco Pieroni、Jonne M.M. Laurila、Vladimir Perovic、Sabrina Tassini、Elisa Azzali、Gabriele Costantino、Sanja Glisic、Danica Agbaba、Mika Scheinin、Katarina Nikolic、Marco Radi、Nevena Veljkovic

  DOI：10.1016/j.bmc.2016.05.043

  日期：2016.7

  The clonidine-like central antihypertensive agent rilmenidine, which has high affinity for I-1-type imidazoline receptors (I-1-IR) was recently found to have cytotoxic effects on cultured cancer cell lines. However, due to its pharmacological effects resulting also from alpha(2)-adrenoceptor activation, rilmenidine cannot be considered a suitable anticancer drug candidate. Here, we report the identification of novel rilmenidine- derived compounds with anticancer potential and devoid of alpha(2)-adrenoceptor effects by means of ligand-and structure-based drug design approaches. Starting from a large virtual library, eleven compounds were selected, synthesized and submitted to biological evaluation. The most active compound 5 exhibited a cytotoxic profile similar to that of rilmenidine, but without appreciable affinity to alpha(2)-adrenoceptors. In addition, compound 5 significantly enhanced the apoptotic response to doxorubicin, and may thus represent an important tool for the development of better adjuvant chemotherapeutic strategies for doxorubicin-insensitive cancers. (C) 2016 Elsevier Ltd. All rights reserved.